Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904036 | 0.84 | CES2 (0.44) | ALDH1A1ALOX15TSHRHPGDSMN1; SMN2 | |
| SCHEMBL6949321 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL8402762 | 0.81 | ALDH1A1 (0.62) | ALDH1A1ALOX15CA12CA1CA2 | |
| SCHEMBL31186401 | 0.81 | ALDH1A1 (0.62) | ALDH1A1ALOX15CA12CA1CA2 | |
| SCHEMBL4645833 | 0.81 | TSHR (0.48) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL10892063 | 0.81 | AKR1C3 (0.55) | ALDH1A1MAPTLMNAAKR1C3CDC25B | |
| SCHEMBL10616138 | 0.80 | KDM4E (0.50) | ALDH1A1TSHRKDM4EHPGDMAPT | |
| SCHEMBL14776191 | 0.79 | G6PD (0.55) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL27938100 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ALOX15CA12CA1CA2 | |
| SCHEMBL3369246 | 0.79 | ALDH1A1 (0.59) | ALDH1A1ALOX15CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | claimed |
| WO-2023146844-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230234931-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | UNIVERSITY OF HOUSTON SYSTEM | 2023-07-27 | — | — | US | disclosed |
| US-20230176481-A1 | FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-06-08 | — | — | US | disclosed |
| CN-115398342-A | Film-forming composition | 日产化学株式会社 | 2022-11-25 | — | — | CN | disclosed |
| US-9040268-B2 | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas | COSKATA, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| EP-1865049-B1 | CLEANING AGENT FOR THERMOSTATIC CHAMBERS | WAKO PURE CHEM IND LTD (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-2758540-A1 | METHOD FOR CONTROLLING UNDESIRABLE BYPRODUCTS FORMATION CAUSED BY CONTAMINATING ORGANISMS IN THE PRODUCTION OF ETHANOL FROM SYNGAS | Coskata Energy Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| CN-103958690-A | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas | COSKATA INC | 2014-07-30 | — | — | CN | disclosed |
| US-8669375-B2 | Process for producing ester compound | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| EP-0594257-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5306818-A | Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-04-26 | — | — | US | disclosed |
| US-5296496-A | Treating degenerative diseases | STERLING WINTHROP INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5250696-A | Treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234931-A1 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | PTGES, PTGES2, PTGS1 | ALDH1A1 263/4885ALOX15 87/4885TSHR 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.